2 unknown, 1 completed, 1 recruiting, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Graft Failure: new trials by email Literature Review of Graft Failure trials Research Report on Graft Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Ruxolitinib - Sickle Cell Disease, Hematopoetic Stem Cell Transplant | Phase 1 / Phase 2 | Recruiting | Arkansas Children's Hospital Research Institute | 24 | 2026-06-08 | 2026-06-04 |
| Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis WJ-MSC infusion - Allogeneic Disease, GVHD,Acute | Phase 1 | Unknown | Central Hospital, Nancy, France | 12 | 2023-09-01 | 2023-05-11 |
| EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs EVLP-DCD Group - Disorders Related to Lung Transplantation, Graft Failure | Phase 1 | Unknown | Policlinico Hospital | 10 | 2014-10-01 | 2014-11-26 |
| Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation EVLP Group - Disorder Related to Lung Transplantation, Brain Death | Phase 1 | Completed | Policlinico Hospital | 7 | 2011-01-01 | 2013-10-23 |
| Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H Fludarabine, CAMPATH 1H, FK506 - Graft Failure | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 40 | 2000-12-01 | 2020-01-18 |
Anemia, Sickle Cell (1) · Brain Death (1) · Primary Graft Dysfunction (1)
Anemia (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Coma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Consciousness Disorders (1) · Death (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Hemoglobinopathies (1) · Nervous System Diseases (1)
Alemtuzumab (1) · Stem Cell Transplantation (1) · Tacrolimus (1) · fludarabine (1) · ruxolitinib (1)
Policlinico Hospital (2) · Arkansas Children's Hospital Research Institute (1) · Baylor College of Medicine (1) · Central Hospital, Nancy, France (1)
Italy (2) · United States (2)
Franco Valenza, MD (2) · Laura McLaughlin, MD (1) · Robert K. Krance, MD (1)
2023 (1)